Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 4 December 2024
Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 23 April 2025
Teprotumumab for treating thyroid eye disease [ID6432]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 20 August 2025
Glaucoma - lerdelimumab (CAT-152) [ID383]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Abicipar pegol for treating wet age-related macular degeneration ID1533Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Port Delivery System with ranibizumab for treating wet age-related macular degeneration [ID3983]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pegcetacoplan for treating geographic atrophy [ID4041]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC